ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

resmetirom

Also written as “Resmetirom”, “MGL-3196” and “VIA-3196”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases · Fibrosis · Liver Cirrhosis, led by 3 companies.

Drug pageResmetirom: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 25, 202622 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Madrigal Pharmaceuticals207 open or runningphase 4since Aug 25, 2026Jun 2, 2011Dec 2026phase 3 · NCT05500222
Nabiqasim Industries (Pvt)its history only11 open or runningphase 4since Nov 18, 2025Nov 18, 2025none ahead
Sagimet Biosciencesits history only10 open or runningphase 1since Oct 8, 2025Oct 8, 2025none ahead

Also a collaborator on its studies: Celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Madrigal Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jun 2, 2011.

  1. Jan 30, 2017Phase 2 study in Heterozygous Familial HypercholesterolemiaNCT03038022 · 116 enrolled · Denmark, Netherlands, Norway
  2. Jul 14, 2017Phase 1 study in HealthyNCT03220165 · 8 enrolled · United States
  3. Jan 22, 2018Phase 1 study in HealthyNCT03413124 · 16 enrolled · United States
  4. Jun 9, 2018Named resmetiromINNProposed as its International Nonproprietary Name in WHO's List 119 · before, MGL-3196, VIA-3196
  5. Mar 26, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT03900429 · 1,759 enrolled · United States, Australia, Austria and more
  6. Dec 11, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT04197479 · 1,343 enrolled · United States, Puerto Rico
  7. Oct 22, 2020Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT04643795 · 87 enrolled · United States
  8. Dec 10, 20202 phase 1 studies in HealthyNCT04671069, NCT04671056
  9. Jun 18, 2021Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT04951219 · 810 enrolled · United States, Puerto Rico
  10. Aug 11, 2022Phase 3 study in Liver CirrhosisNCT05500222 · 845 enrolled · United States, Belgium, Canada and more
  11. Apr 30, 2024Phase 1 study in Renal InsufficiencyNCT06397872 · 28 enrolled · United States
  12. Jan 7, 2026Phase 2 study in FibrosisNCT07335601 · 120 planned · United States, Canada
  13. Aug 10, 2026Phase 2 study in Liver DiseasesNCT07763015 · 61 planned · United States
  14. Aug 25, 2026Phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07848191 · 150 planned · United States
  15. Aug 25, 2026Phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07830758 · 90 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Liver CirrhosisNCT05500222
  2. Mar 2027Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT04951219
  3. Nov 2027Primary completion: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07848191
  4. Nov 2027Primary completion: phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07830758

TargetBeta

THRB →read by rule
“Thyroid hormone receptor beta-1 agonist”ChEMBL 37, by rule

Other programs on THRB

ProgramCompanyFurthest phaseStudies
KYLO-0603Sino Biopharmaceuticalphase 22
CG-0416rulehongkong-curegene-innovation-co-limitedphase 11
KPC000154rulekunming-pharmaceuticals-incphase 11

Studies

All 20 Madrigal Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07848191MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States4RecruitingNov 2027150
NCT07830758MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States1RecruitingNov 202790
NCT07763015Liver Diseases · United States2RecruitingJul 202961
NCT07335601Fibrosis · United States, Canada2RecruitingAug 2028120
NCT06397872Renal Insufficiency · United States1CompletedSep 16, 202428
NCT05500222Liver Cirrhosis · United States, Belgium, Canada and more3Active, not recruitingDec 2026845
NCT04951219Non-alcoholic Fatty Liver Disease · United States, Puerto Rico3Active, not recruitingMar 2027810
NCT04671069Healthy · United States1CompletedAug 30, 201920
NCT04671056Healthy · United States1CompletedDec 11, 201816
NCT04643795Non-alcoholic Fatty Liver Disease · United States1CompletedAug 4, 202187
NCT04197479Non-alcoholic Fatty Liver Disease · United States, Puerto Rico3CompletedJan 6, 20231,343
NCT03900429Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more3Active, not recruitingJan 20281,759
NCT03413124Healthy · United States1CompletedFeb 17, 201816
NCT03220165Healthy · United States1CompletedSep 3, 20178
NCT03038022Heterozygous Familial Hypercholesterolemia · Denmark, Netherlands, Norway2CompletedJan 15, 2018116
NCT02912260Non-alcoholic Fatty Liver Disease · United States2CompletedOct 25, 2017125
NCT02749578Healthy · United States1CompletedMay 201614
NCT02542969Healthy · United States1CompletedOct 201525
NCT01519531Drug Safety · United States1CompletedNov 201248
NCT01367873Drug Safety · United States1CompletedOct 201172

How it is read

Names in the registry

  • “Resmetirom”, 9 entries
  • “MGL-3196”, 8 entries
  • “VIA-3196”, 2 entries
  • “Rezdiffra”, 1 entry
  • “MGL-3196 (resmetirom)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.